导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.65% | 3761/4345 |
| 近一周 | -3.73% | 4413/4962 |
| 近一月 | -4.64% | 3047/4922 |
| 近一季 | -0.54% | 1007/4747 |
| 近半年 | -13.81% | 3566/4477 |
| 近一年 | -22.09% | 3628/4016 |
| 近两年 | 1.95% | 2626/2712 |
| 近三年 | -30.16% | 2014/2054 |
| 成立以来 | 119.09% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.71% 3922/4961 |
-13.88% 4526/5312 |
- - |
- - |
| 2025 | -5.18% 3370/4813 |
-1.35% 2645/3635 |
-3.29% 3423/4076 |
3.74% 3724/4524 |
-4.20% 3416/4813 |
| 2024 | -3.77% 2220/3463 |
-0.99% 1161/2808 |
-12.09% 2588/3014 |
17.24% 1229/3129 |
-5.69% 2580/3463 |
| 2023 | -18.01% 1777/2656 |
3.24% 1233/2280 |
-13.16% 2202/2385 |
-1.26% 500/2515 |
-7.38% 2134/2655 |
| 2022 | -13.34% 325/2207 |
-20.29% 1535/1919 |
19.80% 74/2016 |
-11.73% 570/2113 |
2.82% 828/2208 |
| 2021 | -6.85% 1022/1822 |
-9.83% 1111/1255 |
9.73% 526/1330 |
-10.89% 1246/1466 |
5.65% 277/1822 |
| 2020 | 92.51% 19/1250 |
0.26% 166/1028 |
26.65% 142/1067 |
21.29% 42/1164 |
24.99% 29/1184 |
| 2019 | 61.30% 48/1092 |
39.19% 53/739 |
10.02% 8/788 |
0.95% 441/850 |
4.34% 809/918 |
| 2018 | -18.55% 147/834 |
- - |
8.90% 4/631 |
-5.12% 363/660 |
-15.68% 617/682 |
| 2017 | 36.65% 29/714 |
- - |
- - |
- - |
- - |
| 2016 | 1.85% 91/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证食品饮料ETF联接A VS. 长安沪深300非周期A(740101) |